Ramelteon

每周药品注册获批数据，分门别类呈现，一目了然。(3.17-3.23） 新药上市申请药品名称企业注册分类受理号SHR0302片江苏恒瑞医药股份有限公司1CXHS2300071特瑞普利单抗注射液上海君实生物医药科技股份有限公司2.2CXSS2400070特瑞普利单抗注射液上海君实生物医药科技股份有限公司2.2CXSS2400069 新药临床申请药品名称企业注册分类受理号BG-68501片百济神州(苏州)生物科技有限公司1CXHL2500064BG-68501片百济神州(苏州)生物科技有限公司1CXHL2500063BG-68501片百济神州(苏州)生物科技有限公司1CXHL2500062BGB-43395片百济神州(苏州)生物科技有限公司1CXHL2500069BGB-43395片百济神州(苏州)生物科技有限公司1CXHL2500068BGB-43395片百济神州(苏州)生物科技有限公司1CXHL2500066KHN702片成都康弘药业集团股份有限公司1CXHL2500057KHN702片成都康弘药业集团股份有限公司1CXHL2500056KHN702片成都康弘药业集团股份有限公司1CXHL2500055HRS-9813胶囊广东恒瑞医药有限公司1CXHL2500052HRS-5817注射液上海拓界生物医药科技有限公司1CXHL2500040HS-10516胶囊江苏豪森药业集团有限公司1CXHL2500031HS-10516胶囊江苏豪森药业集团有限公司1CXHL2500030ABSK061胶囊装微片上海和誉生物医药科技有限公司1CXHL2500039ABSK061胶囊装微片上海和誉生物医药科技有限公司1CXHL2500038ABSK061胶囊装微片上海和誉生物医药科技有限公司1CXHL2500037ABSK061胶囊装微片上海和誉生物医药科技有限公司1CXHL2500036SYH2067胶囊石药集团百克(山东)生物制药股份有限公司1CXHL2500027SYH2067胶囊石药集团百克(山东)生物制药股份有限公司1CXHL2500026SYH2067胶囊石药集团百克(山东)生物制药股份有限公司1CXHL2500025HRS-1738注射液天津恒瑞医药有限公司1CXHL2500012QLS1209片齐鲁制药有限公司1CXHL2500011QLS1209片齐鲁制药有限公司1CXHL2500010ETS-006片无锡奕拓医药科技有限责任公司1CXHL2500015ETS-006片无锡奕拓医药科技有限责任公司1CXHL2500014SIR2501片维泰瑞隆(北京)生物科技有限公司1CXHL2500009SIR2501片维泰瑞隆(北京)生物科技有限公司1CXHL2500008SRSD216注射液靖因药业(上海)有限公司1CXHL2401496IPG8294片南京艾美斐生物医药科技有限公司1CXHL2401484IPG8294片南京艾美斐生物医药科技有限公司1CXHL2401483IPG8294片南京艾美斐生物医药科技有限公司1CXHL2401482IPG8294片南京艾美斐生物医药科技有限公司1CXHL2401481IPG8294片南京艾美斐生物医药科技有限公司1CXHL2401480IPG8294片南京艾美斐生物医药科技有限公司1CXHL2401479QY201片启元生物(杭州)有限公司1CXHL2401459QY201片启元生物(杭州)有限公司1CXHL2401458QY201片启元生物(杭州)有限公司1CXHL2401457GW906注射液成都国为生物医药有限公司1CXHL2401452QLM2011齐鲁制药(海南)有限公司2.2CXHL2500041BN170614山东百诺医药股份有限公司2.2CXHL2500003KLA514-2片四川科伦药业股份有限公司2.2CXHL2401466BCM235双释干混悬剂上海云晟研新生物科技有限公司2.2CXHL2401409BCM235双释干混悬剂上海云晟研新生物科技有限公司2.2CXHL2401408BCM882胶囊上海云晟研新生物科技有限公司2.3CXHL2500006BCM882胶囊上海云晟研新生物科技有限公司2.3CXHL2500005TQB2210注射液正大天晴药业集团南京顺欣制药有限公司1CXSL2500136注射用TQB2934正大天晴药业集团南京顺欣制药有限公司1CXSL2500044JSKN016注射液江苏康宁杰瑞生物制药有限公司1CXSL2500033JSKN016注射液江苏康宁杰瑞生物制药有限公司1CXSL2500027注射用SHR-9803江苏恒瑞医药股份有限公司1CXSL2500026注射用JS212上海君实生物医药科技股份有限公司1CXSL2500023注射用ZL-1310再鼎医药(上海)有限公司1CXSL2500025SYS6040石药集团巨石生物制药有限公司1CXSL2500016DS010注射液达石药业(广东)有限公司1CXSL2500018MNO-863肠溶胶囊慕恩(广州)生物科技有限公司1CXSL2500011MNO-863肠溶胶囊慕恩(广州)生物科技有限公司1CXSL2500010MNO-863肠溶胶囊慕恩(广州)生物科技有限公司1CXSL2500009HLX79 注射液上海复宏汉霖生物技术股份有限公司1CXSL2500008注射用SSS59沈阳三生制药有限责任公司1CXSL2500006DNTH103注射液元羿生物科技(上海)有限公司1CXSL2400933注射用SHR-A2102苏州盛迪亚生物医药有限公司1CXSL2400915HS-20117注射液上海翰森生物医药科技有限公司1CXSL2400917人脐带间充质干细胞注射液广州达博生物制品有限公司1CXSL2400912依苏帕格鲁肽α注射液上海银诺生物医药工程有限公司1CXSL2400908依苏帕格鲁肽α注射液上海银诺生物医药工程有限公司1CXSL2400907依苏帕格鲁肽α注射液上海银诺生物医药工程有限公司1CXSL2400906依苏帕格鲁肽α注射液上海银诺生物医药工程有限公司1CXSL2400905IMC001注射液成都易慕峰生物科技有限公司1CXSL2400901NWRD09注射液诺未生物技术(无锡)有限公司1CXSL2400899NCR102注射液中盛溯源(广州)生物科技有限公司1CXSL2400897注射用YB-01元本(珠海横琴)生物科技有限公司1CXSL2400895SENL103自体T细胞注射液河北森朗生物科技有限公司1CXSL2400892注射用重组A型肉毒毒素北京博特维克生物技术有限公司2.4CXSL2500043 仿制药申请药品名称企业注册分类受理号硝普钠注射液中润药业有限公司3CYHS2500433硫酸特布他林口服溶液宝利化(南京)制药有限公司3CYHS2500186西格列汀二甲双胍缓释片南京易亨制药有限公司3CYHS2404322顺铂注射液华夏生生药业(北京)有限公司3CYHS2401913乙酰半胱氨酸注射液湖南华纳大药厂股份有限公司3CYHS2401507复方聚乙二醇电解质散(II)陕西丽彩药业有限公司3CYHS2401307腺苷钴胺胶囊杭州康恩贝制药有限公司3CYHS2400042氟[18F]脱氧葡糖注射液广东高尚医药科技有限公司3CYHS2303442盐酸布比卡因注射液南京海融制药有限公司3CYHS2303207盐酸布比卡因注射液南京海融制药有限公司3CYHS2303206吡格列酮二甲双胍片寿光富康制药有限公司3CYHS2302323米诺地尔搽剂杭州民生健康药业股份有限公司3CYHS2301940米诺地尔搽剂杭州民生健康药业股份有限公司3CYHS2301939盐酸多巴酚丁胺注射液仁合益康集团有限公司3CYHS2301904复方聚乙二醇(3350)电解质口服溶液重庆迈川医药科技有限公司3CYHS2301787铝碳酸镁混悬液太康海恩药业有限公司3CYHS2301710西格列汀二甲双胍缓释片宁波美舒医药科技有限公司3CYHS2301432黄体酮注射液丽珠集团利民制药厂3CYHS2301111羧甲司坦口服溶液浙江易泽达医药科技有限公司3CYHS2300804地塞米松磷酸钠注射液湖南醇健医药有限公司3CYHS2300779骨化三醇注射液河南泰丰生物科技有限公司4CYHS2500496利伐沙班片拜耳医药保健有限公司4CYHS2402846利伐沙班片拜耳医药保健有限公司4CYHS2402845利伐沙班片拜耳医药保健有限公司4CYHS2402844利伐沙班片拜耳医药保健有限公司4CYHS2402843美沙拉秦肠溶片江西山香药业有限公司4CYHS2401219聚乙烯醇滴眼液吉林敖东药业集团延吉股份有限公司4CYHS2400434多索茶碱注射液湖北午时医药研究院有限公司4CYHS2400172妥布霉素滴眼液浙江视方极医药科技有限公司4CYHS2400049美阿沙坦钾片山东朗诺制药有限公司4CYHS2303658美阿沙坦钾片山东朗诺制药有限公司4CYHS2303656卡泊三醇倍他米松软膏重庆华邦制药有限公司4CYHS2303655卡泊三醇倍他米松软膏重庆华邦制药有限公司4CYHS2303654莫匹罗星软膏重庆苯立方医药科技有限公司4CYHS2303525盐酸尼卡地平注射液成都旭阳永健医药科技有限公司4CYHS2303436伏立康唑干混悬剂石家庄四药有限公司4CYHS2303395吡仑帕奈口服混悬液江西科睿药业有限公司4CYHS2303309艾拉莫德片扬子江药业集团有限公司4CYHS2303123间苯三酚注射液亚宝药业四川制药有限公司4CYHS2303073培哚普利氨氯地平片(III)江苏万珺医药科技有限公司4CYHS2303047乳果糖口服溶液云鹏医药集团有限公司4CYHS2303044复方电解质注射液辽宁民康制药有限公司4CYHS2302982多巴丝肼片武汉人福药业有限责任公司4CYHS2302919洛索洛芬钠凝胶贴膏武汉法玛星制药有限公司4CYHS2302894拉坦噻吗滴眼液兆科(广州)眼科药物有限公司4CYHS2302869聚乙烯醇滴眼液珠海联邦制药股份有限公司中山分公司4CYHS2302860利丙双卡因乳膏南京长澳制药有限公司4CYHS2302778玻璃酸钠滴眼液宁夏康亚药业股份有限公司4CYHS2302642玻璃酸钠滴眼液宁夏康亚药业股份有限公司4CYHS2302641硝酸甘油舌下片南京斯泰尔医药科技有限公司4CYHS2302396他达拉非片金鸿药业股份有限公司4CYHS2302336注射用硫酸艾沙康唑齐鲁制药(海南)有限公司4CYHS2302040盐酸二甲双胍片重庆吉斯瑞制药有限责任公司4CYHS2302053聚乙二醇4000散福州基石医药科技有限公司4CYHS2301943钆特酸葡胺注射液华润双鹤药业股份有限公司4CYHS2301695硝酸甘油舌下片山东威智百科药业有限公司4CYHS2301551硝酸甘油舌下片山东威智百科药业有限公司4CYHS2301550依维莫司片浙江康润制药有限公司4CYHS2301019依维莫司片浙江康润制药有限公司4CYHS2301018四价流感病毒裂解疫苗安徽智飞龙科马生物制药有限公司3.3CXSS2300059利拉鲁肽注射液珠海联邦制药股份有限公司3.3CXSS2300067利多卡因软膏北京中泰邦医药科技有限公司3CYHL2500013利多卡因软膏北京中泰邦医药科技有限公司3CYHL2500012丙酸倍氯米松吸入气雾剂合肥力成药业有限公司3CYHL2500009注射用盐酸兰地洛尔天津红日药业股份有限公司3CYHL2400285雷美替胺片四川科瑞德制药股份有限公司3CYHL2400276注射用盐酸兰地洛尔中山万汉制药有限公司3CYHL2400272甲苯磺酸卢美哌隆胶囊宜昌人福药业有限责任公司3CYHL2400269羟乙基淀粉130/0.4电解质注射液山东齐都药业有限公司4CYHL2400284羟乙基淀粉130/0.4电解质注射液山东齐都药业有限公司4CYHL2400283 进口申请药品名称企业注册分类受理号阿可替尼胶囊AstraZeneca Pty Ltd.5.1JXHS2400047氢溴酸他泽司他片Epizyme, Inc.5.1JXHS2400046注射用戈沙妥珠单抗Gilead Sciences, Inc.3.1JXSS2400008达格列净片Hetero Labs Limited5.2JYHS2400017达格列净片Hetero Labs Limited5.2JYHS2400016AZD2936AstraZeneca AB1JXSL2500007AZD2936AstraZeneca AB1JXSL2500006TremelimumabMedImmune LLC2.2JXSL2500005TremelimumabMedImmune LLC2.2JXSL2500004 中药相关申请药品名称企业注册分类受理号ZYY-742凝胶扬子江药业集团江苏龙凤堂中药有限公司1.1CXZL2500001养巢颗粒漳州片仔癀药业股份有限公司1.1CXZL2400098连参更年颗粒江苏康缘药业股份有限公司1.1CXZL2400095散热止咳颗粒新奇康药业股份有限公司1.1CXZL2400091玉屏风袋泡茶广州白云山陈李济药厂有限公司2.3CXZL2400100三七通舒胶囊成都神鹤药业有限责任公司4CYZS2400002 注：橙色字体部分结论为不批准或收到通知件；

Updated label includes new data in Section 12.2, detailing serotonin 5-HT2C partial agonist activity and norepinephrine transporter inhibition, highlighting Qelbree’s multimodal pharmacodynamicsQelbree is the first ADHD treatment to meet its post marketing requirement and receive labeling approval following the 2019 FDA guidance on Clinical Lactation Studies1 ROCKVILLE, Md., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced that the U.S. Food and Drug Administration (FDA) has approved an update for the label for Qelbree (viloxazine extended-release capsules) to include new pharmacodynamic data in Section 12.2. The updated label describes viloxazine’s partial agonist activity at the serotonin 5-HT2C receptor and inhibition of the norepinephrine transporter, reinforcing its multimodal pharmacodynamic profile. The mechanism of action of Qelbree, though unclear, is thought to be through inhibiting the reuptake of norepinephrine. Additionally, the updated label now includes new lactation data for breastfeeding women with attention-deficit/hyperactivity disorder (ADHD), showing that the transfer of Qelbree into breastmilk is low. Qelbree is approved for use in patients ages 6 years and older with ADHD. “This label update and new data deepens our understanding of Qelbree, providing valuable insights to help support treatment decision-making for people living with ADHD,” says Dr. Stephen M. Stahl, M.D., PhD, DSc (Hon.) Distinguished Health Sciences Clinical Professor of Psychiatry and Neuroscience, University of California Riverside and Adjunct Professor of Psychiatry, University of California San Diego. “The updated pharmacodynamic data, which highlights viloxazine’s effects on the serotonin 5-HT2C receptor and inhibition of the norepinephrine transporter, adds depth to our understanding of Qelbree’s multimodal pharmacodynamics.” The update to include lactation data in the label (Section 8.2) follows the 2019 FDA guidance suggesting lactation studies be conducted to inform breastfeeding with drug use recommendations and is based on a study involving 15 healthy lactating women.¹ The study evaluated the secretion of viloxazine and its metabolite (5-HVLX-gluc) into breast milk following a multi-dose (600 mg daily for three days) regimen of viloxazine. Results showed that the estimated daily infant dose (using a nominal infant body weight of 6 kg) of viloxazine and 5-HVLX-gluc was 0.085 mg/kg and 0.00595 mg/kg, respectively, and the relative infant dose was approximately 1% and 0.07%, respectively, of the weight-normalized maternal daily dose (8.58 mg/kg) of viloxazine. These data support that the transfer of viloxazine into breastmilk is low. The study did not specifically evaluate the effects of viloxazine on breastfed infants or milk production, nor is there additional data regarding these effects. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Qelbree and any potential adverse effects on the breastfed child from Qelbree or from the underlying maternal condition. “By expanding Qelbree’s label to include new data on the pharmacodynamics and use in breastfeeding mothers, Supernus continues to empower healthcare providers and patients to make informed treatment decisions,” says Jack A. Khattar, President and Chief Executive Officer of Supernus Pharmaceuticals. “We are committed to building the body of evidence surrounding Qelbree’s use within the ADHD space and providing an effective treatment option for those living with ADHD.” INDICATION Qelbree® (viloxazine extended-release capsules) is a prescription medicine used to treat ADHD in adults and children 6 years and older. IMPORTANT SAFETY INFORMATION Qelbree may increase suicidal thoughts and actions, in children and adults with ADHD, especially within the first few months of treatment or when the dose is changed. Tell your doctor if you or your child have (or if there is a family history of) suicidal thoughts or actions before starting Qelbree. Monitor your or your child’s moods, behaviors, thoughts, and feelings during treatment with Qelbree. Report any new or sudden changes in these symptoms right away. You or your child should not take Qelbree if you or your child: Take a medicine for depression called a monoamine oxidase inhibitor (MAOI) or have stopped taking an MAOI in the past 14 days. Also, you or your child should avoid alosetron, duloxetine, ramelteon, tasimelteon, tizanidine, and theophylline. Qelbree can increase blood pressure and heart rate. Your or your child’s doctor will monitor these vital signs. Qelbree may cause manic episodes in patients with bipolar disorder. Tell your doctor if you or your child show any signs of mania. Do not drive or operate heavy machinery until you know how Qelbree will affect you or your child. Qelbree may cause you or your child to feel sleepy or tired. The most common side effects of Qelbree in patients 6 to 17 years are sleepiness, not feeling hungry, feeling tired, nausea, vomiting, trouble sleeping, and irritability, and in adults, insomnia, headache, sleepiness, tiredness, nausea, decreased appetite, dry mouth, and constipation. These are not all the possible side effects of Qelbree. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. Please see full Prescribing Information, including Boxed Warning and Medication Guide, for Qelbree here. ¹U.S. Food and Drug Administration. (2019). Clinical Lactation Studies: Considerations for Study Design. Guidance for Industry. Retrieved from https://www.fda.gov/media/124749/download. About Supernus Pharmaceuticals, Inc. Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Our diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, epilepsy, migraine, cervical dystonia, and chronic sialorrhea. We are developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. For more information, please visit www.supernus.com. Forward Looking StatementsThis press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements do not convey historical information but relate to predicted or potential future events that are based upon management's current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In addition to the factors mentioned in this press release, such risks and uncertainties include, but are not limited to, the Company’s reporting on preliminary and exploratory open label clinical study on SPN-820, the Company’s ability to sustain and increase its profitability; the Company’s ability to raise sufficient capital to fully implement its corporate strategy; the implementation of the Company’s corporate strategy; the Company’s future financial performance and projected expenditures; the Company’s ability to increase the number of prescriptions written for each of its products and the products of its subsidiaries; the Company’s ability to increase net revenue; the Company’s ability to commercialize its products and the products of its subsidiaries; the Company’s ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies; the Company’s ability to conduct and progress product research and development activities, including the timing and progress of the Company’s clinical trials, and projected expenditures; the Company’s ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize the Company’s product candidates including SPN-820 and SPN-830; the Company’s ability to protect its intellectual property and the intellectual property of its subsidiaries and operate its business without infringing upon the intellectual property rights of others; the Company’s expectations regarding federal, state and foreign regulatory requirements; the therapeutic benefits, effectiveness and safety of the Company’s product candidates including SPN-820; the accuracy of the Company’s estimates of the size and characteristics of the markets that may be addressed by its product candidates; the Company’s ability to increase its manufacturing capabilities for its products and product candidates including SPN-820; the Company’s projected markets and growth in markets; the Company’s product formulations and patient needs and potential funding sources; the Company’s staffing needs; and other risk factors set forth from time to time in the Company’s filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. The Company undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events. CONTACTS: Jack A. Khattar, President and CEOTimothy C. Dec, Senior Vice President and CFOSupernus Pharmaceuticals, Inc.(301) 838-2591 Or INVESTOR CONTACT: Peter VozzoICR Healthcare(443) 213-0505Peter.Vozzo@icrhealthcare.com MEDIA CONTACT: Catherine Fabiano(646) 384-9617Catherine.Fabiano@bcw-global.com